VEDANTA BIOSCIENCES INC.

In News

Vedanta ‘significantly’ reduces headcount to fund lead bacteria cocktail program - Fierce Biotech

Fierce Biotech - Jan 16, 2026

Vedanta Biosciences Secures $60 Million in Funding and Strengthens Leadership Team Ahead of Pivotal Phase 3 Data - BioSpace

BioSpace - Aug 06, 2026

Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection Will Continue as Planned Following Protocol-Specified Interim Analysis - BioSpace

BioSpace - Apr 03, 2026

Vedanta Biosciences Raises $60 Million To Advance Phase 3 VE303 Study - Pulse 2.0

Pulse 2.0 - Aug 06, 2026

Vedanta, PureTech’s microbiome startup, to cut staff after study setback - BioPharma Dive

BioPharma Dive - Aug 14, 2025

Vedanta Biosciences Showcases Innovative Work on its Microbiome-based Therapeutics at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2026 Global Congress - BioSpace

BioSpace - Apr 10, 2026

North America Human Microbiome Market Report 2026-2031, By Drug & Supplement, Disease, and Geo - MarketsandMarkets

MarketsandMarkets - Dec 15, 2025

Member Spotlight: Q&A with Vedanta Biosciences - Massachusetts Biotechnology Council

Massachusetts Biotechnology Council - Jan 02, 2018

Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies - Business Wire

Business Wire - Apr 25, 2023

Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc. - Business Wire

Business Wire - Jan 12, 2021

Vedanta Downsizes by 20% After Phase II Stumble in Ulcerative Colitis - BioSpace

BioSpace - Aug 14, 2025

Vedanta Biosciences Awarded Up to $76.9 Million Including $7.4 Million Upfront from BARDA to Advance the Development of VE303, a Defined Bacterial Consortium for Prevention of C. difficile Infection in High-Risk Patients - Business Wire

Business Wire - Sep 30, 2020

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment